168 related articles for article (PubMed ID: 36118548)
1. Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma.
Marar R; Prathivadhi-Bhayankaram S; Krishnan M
J Hematol; 2022 Aug; 11(4):142-147. PubMed ID: 36118548
[TBL] [Abstract][Full Text] [Related]
2. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.
Kalmuk J; Puchalla J; Feng G; Giri A; Kaczmar J
Cancers Head Neck; 2020; 5():3. PubMed ID: 32025343
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.
Rajapakse P; Andanamala H
World J Oncol; 2022 Apr; 13(2):49-52. PubMed ID: 35571340
[TBL] [Abstract][Full Text] [Related]
5. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
Sadaat M; Jang S
J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis.
Wang C; Sun W; Li Z; Wu T; Fang W
Invest New Drugs; 2023 Dec; 41(6):834-841. PubMed ID: 37897650
[TBL] [Abstract][Full Text] [Related]
7. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
Noseda R; Bertoli R; Müller L; Ceschi A
J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
[TBL] [Abstract][Full Text] [Related]
8. Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study.
Diaz L; Jauzelon B; Dillies AC; Le Souder C; Faillie JL; Maria ATJ; Palassin P
J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902771
[TBL] [Abstract][Full Text] [Related]
9. Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma.
Thummalapalli R; Heumann T; Stein J; Khan S; Priemer DS; Duffield AS; Laterra J; Couzi R; Lim M; Holdhoff M
Case Rep Oncol; 2020; 13(2):508-514. PubMed ID: 32518546
[TBL] [Abstract][Full Text] [Related]
10. Hemophagocytic lymphohistiocytosis in a patient with Goodpasture's syndrome: a rare clinical association.
Basnet A; Cholankeril MR
Am J Case Rep; 2014 Oct; 15():431-6. PubMed ID: 25284133
[TBL] [Abstract][Full Text] [Related]
11. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
Liu LL; Skribek M; Harmenberg U; Gerling M
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
[TBL] [Abstract][Full Text] [Related]
12. Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review.
Wei Y; He W; Sun W; Wu C; Ren D; Wang X; Zhang M; Huang M; Ji N
Transl Cancer Res; 2022 Aug; 11(8):2960-2966. PubMed ID: 36093533
[TBL] [Abstract][Full Text] [Related]
13. TNFAIP3 mutation causing haploinsufficiency of A20 with a hemophagocytic lymphohistiocytosis phenotype: a report of two cases.
Aslani N; Asnaashari K; Parvaneh N; Shahrooei M; Sotoudeh-Anvari M; Shahram F; Ziaee V
Pediatr Rheumatol Online J; 2022 Sep; 20(1):78. PubMed ID: 36064566
[TBL] [Abstract][Full Text] [Related]
14. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
15. Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.
Masood A; Wahab A; Clifford T; Weaver EJ; Ehsan H; El Ayass W
Clin Case Rep; 2021 Dec; 9(12):e05184. PubMed ID: 34917381
[TBL] [Abstract][Full Text] [Related]
16. Hemophagocytic lymphohistiocytosis due to pembrolizumab therapy for adenocarcinoma of the lung.
Doyle JJ; Hall JA; Reely K; Dodlapati J
Proc (Bayl Univ Med Cent); 2021; 34(6):729-730. PubMed ID: 34733004
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis in a patient with non-small cell lung carcinoma.
Oyama S; Shirai T; Abe Y; Tsuchiya M; Inui T; Suhara K; Noto S; Kamimura M
Respirol Case Rep; 2023 Apr; 11(4):e01117. PubMed ID: 36910133
[TBL] [Abstract][Full Text] [Related]
18. A Case Report of Hemophagocytic Lymphohistiocytosis and Meningitis Due to Atezolizumab Treatment for Lung Adenocarcinoma.
Ota H; Munechika M; Tobino K; Uchida K; Muarakami Y
Cureus; 2024 Apr; 16(4):e58253. PubMed ID: 38745801
[TBL] [Abstract][Full Text] [Related]
19. Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review.
Wang S; Wu J; Jing X; Zhang Y; Tang H; Wu J
Hematology; 2019 Dec; 24(1):751-756. PubMed ID: 33138732
[TBL] [Abstract][Full Text] [Related]
20. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the
Al-Samkari H; Snyder GD; Nikiforow S; Tolaney SM; Freedman RA; Losman JA
J Med Genet; 2019 Jan; 56(1):39-42. PubMed ID: 30287596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
